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Abstract 
Background:In sociology, the prevalence of cancer is interpreted as a broken social contract that requires 
behaviour change. Complementary and alternative medicine (CAM) is a vital social phenomenon, whose usage 
is socially patterned out. Perceptions of the limitations of chemotherapy and radiotherapy among cancer patients 
have contributed to the preference for CAM use, particularly plant-derived polysaccharides like HemoHIM, 
which contain cisplatin. This research was undertaken to show whether co-administration of vitamin C with 
cisplatin in chemotherapy can prevent or reduce the side-effects of cisplatin nephrotoxicity.  
Objectives:The objective of this study was to overturn social perceptions of conventional therapy as associated 
with nephrotoxicity. It investigates the renoprotective effects of high-dose vitamin C by performing an animal 
experiment to determine body weight, organ weight, and biochemical blood parameters; as well as to measure 
inflammatory cytokines. 
Design:Mice were randomly divided into five groups (control; and 500, 1000, and 2000 mg/kg of vitamin C with 
cisplatin). All groups except for the control group were intraperitoneally injected with 5- mg/kg cisplatin for 10 
days, and the mice in the respective groups were orally administered each 500-, 1000-, 2000- mg/kg vitamin C 2 
h prior to cisplatin treatment. After 10 days, the mice were sacrificed, and their blood samples and kidney tissues 
were obtainedfor further analysis. 
Setting and location:Republic of Korea 
Methods:Blood samples from animal experiments and tissue preparation were analyzed using real-time 
quantitative polymerase chain reaction. 
Results:The intraperitoneal injection of cisplatinreduced body weight, and elevated levels of blood urea nitrogen, 
serum creatinine, and uric acid. It also triggered an inflammatory response in the mouse kidney by inducing the 
pro-inflammatory cytokines TNFα, IL-6, and IL-1β and increasing in the expression of iNOS, and IL-4. Renal 
injury was decreased by the administration of vitamin C; the oral administration of vitamin C (500, 1000, 2000 
mg/kg) decreased or normalized the renal function through the attenuation of cisplatin-induced inflammatory 
cytokines and the modulation of biochemical parameters (ALT, AST, cholesterol, TG, HDL, LDL, blood urea 
nitrogen, creatinine, and Uric acid) following the intraperitoneal injection of cisplatin.  
Conclusion:The results of our present study suggest that the co-administration of vitamin C with cisplatin 
chemotherapy is a promising method to prevent or reduce the side effects of cisplatin nephrotoxicity. These 
findings can remodel how the Korean society thinks, approaches and fights cancer by showing how 
nephrotoxicity can be counteracted to ensure social acceptance of CAM as an adjunctive to cisplatin therapy. 
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Introduction 
Complementary and alternative medicine (CAM) is a vital social phenomenon in South Korea. A high usage of 
CAM has been observed particularly among elderly South Koreans with cancer.1 There are also indications that 
CAM can be a primary interconnected source of stability and support for health care delivery in remote and rural 
regions.2 Such phenomenon is socially patterned out across South Korea. In effect, CAM refers to a combination 
of socially diverse therapeutic and patient care systems that normally considered as an alternative to 
conventional medicine.3 They are culturally diverse, and their administration may depend on the social dynamics 
of people in certain cultures. While the growing popularity of CAM has become certain in South Korea in recent 
decades, it is unclear to what extent it is effective when used as standalone therapeutic modality, in comparison 
to conventional medicine like radiotherapy or chemotherapy. 
A growing body of research is continuing to demonstrate that perceptions of the limitations of 
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chemotherapy and radiotherapy among cancer patients have contributed to the preference for CAM use, or the 
desire for natural and holistic therapies.4 In spite of this, clinicians have argued that this is because of a lack of 
clear information on the real efficacies and limitations of conventional treatment, the increasing advertisements 
for CAM, or the desire for holistic or natural treatments.5 Although clinicians care for many cancer patients 
using CAM in everyday clinics, little information is available regarding CAM, and there are, as yet, no available 
and definitive practical guidelines for CAM usage in Korea. Studies that have examine usage of CAM among 
Korean cancer patients have identified some of the parameters for using the therapy – other than social factors - 
as including the cost, prevalence, side-effects and subjective-effects.6 Additional parameters are the clinical 
attributes of users in comparison to non-users and patients and doctor’s expectations. Among the findings made 
in research undertaken in Korea is that use of CAM is highly prevalent, with 78.5% of cancer patients having 
used on form of CAM or the other because of its social prevalence. While such findings may not truly reflect the 
accurate prevalence of CAM use, many of the participants were in advanced cancer stages. This could be linked 
to the high prevalence of CAM use rather than conventional therapy.This indicates that the prevalence of CAM 
is a cause for concern. For this reason, critical action is necessary to remodel how the Korean society thinks, 
approaches and fights cancer. In sociology, the prevalence of cancer could be interpreted as a broken social 
contract requiring conceptual frameworks that can inspire behaviour change. For this reason, there is a need for 
researches that can push forward discussions to rethink the manner in which conventional therapy is approached 
and communicated.7 Approaching the prevalence of cancer as a consequence of broken social contract is one 
way in which this can be achieved. Equally, this undertaking calls for a combination of ideas drawn from 
biology, biochemistry, computational medicine, and physics. An infusion of ideas from these fields of study is 
expected to illuminate aspects of cancer biology that could be applied to inspire consideration of conventional 
therapy as an adjunctive of CAM.  
While it has been posited across some conventional medicine research that CAM may not inhibit the growth 
of tumours when used in place of conventional treatments.6,7,8 A number of studies undertaken across some 
societies in Asia – such as China, Japan and Korea,  have showed that plant-derived polysaccharides – which are 
used as CAM - have some anticancer elements like Cisplatin.8 For instance, studies on the efficacy of an herbal 
combination of CAM known as HemoHIM have indicated that has immunotherapy properties.9 HemoHIM is 
designed to safeguard the self-renewal tissues and to encourage the recovery of the immune system. It is made 
by adding polysaccharides to a hot water extract of an herbal mixture of Paeonia Radix, Cnidium Rhizoma, and 
Angelica Radix. In their study, Park et al. examined the use of HemoHIM to augment the anticancer effects of 
cisplatin and to restore immune functions.10 They found HemoHIM to enhance antitumor efficacies of cisplatin. 
While this gives some hope in the use of CAM, cisplatin has objectionable side-effects like severe nephrotoxicity. 
In the context of this research, there is significant rationale to carry out a research that can overturn social 
perceptions of conventional therapy as associated with nephrotoxicity – a common side effect in patients with 
cancer receiving cisplatin therapy. Fundamentally, oxidative stress, production of inflammatory cytokines, and 
cell death are the major pathological mechanisms underlying cisplatin-induced nephrotoxicity. Therefore, 
undertaking a research to show how nephrotoxicity can be reduced could be beneficial in changing the prevalent 
social perceptions regarding side-effects of conventional therapy such as chemotherapy. 
Against this backdrop, a study was undertaken to show whether co-administration of vitamin C with 
cisplatin chemotherapy can prevent or reduce the side-effects of cisplatin nephrotoxicity. The present study 
investigated the renoprotective effects of high-dose vitamin C by carrying out an animal experiment to determine 
body weight, organ weight, and biochemical blood parameters; as well as to measure inflammatory cytokines. 
 
Literature review 
Cancer therapy has traditionally been driven by the conception of eradicating proliferating cancer cells by 
inducing cell death of the dividing tumour cells using chemotherapeutic, or radiotherapy. Over the years, 
chemotherapy has become the foremost therapeutic modality universally used in the treatment various cancers. 
Research evidence has also showed that, use of chemotherapy or radiotherapy as standalone therapeutic 
modalities cannot attain acceptable therapeutic outcomes, including attaining a complete remission of tumours.11 
They have also been found to contribute to serious side-effects in spite of being administered at therapeutically 
acceptable doses, leading to a preference for CAM.2 
The growing prevalence of CAM usage differs across countries depending on diverse social, demographic, 
and cultural attributes of particular population, such as age, ethnicity, gender, income, and level of education.12 
Compared to many Western or Asian countries, use of traditional medicine is prevalent even in the South Korean 
national healthcare system. This could be attributed to the reality that the popularity of traditional medicine has 
witnessed a sharp rise since the early 1990s.13 Among the demographic patterns of the preference of CAM use is 
the perception of their efficacy depending on age. Already, some studies have indicated that the patterns of 
preferences of CAM use differs substantially among the young and older adults in South Korea, with the latter 
showing a greater inclination. Kim et al. also explored whether reasons for CAM use differ among young adults 
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depending on their physical fitness and found that use of CAM tended to be higher among patients who use 
nonsurgical and nonpharmacological approaches.14 
In the wider Korean society, medical practitioners have questioned the efficacy of CAM. It may tempt 
sociologists to demonstrate indifference to answer that question as they consider CAM to be a fundamental 
social phenomenon, which is widely considered by users to be effective and necessary. Nevertheless, 
sociologists have, in recent decades, demonstrated the readiness to engage more critically with technical 
questions that require medical expertise by falling back on science studies and sociology to understand how 
CAM works in relation to conventional biomedical therapies like chemotherapy or radiotherapy.15 Of particular 
interest to sociologists is the realization the efficacy of chemotherapy and radiotherapy cannot guaranteed 
without CAM. 
In the case of South Korea, studies have showed that the primary reason for preferring CAM therapies 
among, 31.6% of participants surveyed was to prevent diseases and promote health, and that this was largely 
influenced by the popularity of Korean Oriental Medicine (KOM). An estimated 75% of adults in Korea were 
found to have also used a form of CAM in the last year.16 The prevalence rate of CAM usage in South Korea is 
higher than that of Western countries. This prevalence rates were based on social, economic, demographic and 
gender factors. For instance, preference for CAM to cisplatin therapy tends be higher among men than women. 
In relation to socioeconomic and demographic factors, Koreans in the age bracket of 50-29 years old with lower 
educational attainment, higher religious values, higher family income, and higher marital experience were found 
to be more likely to prefer CAM.13 In the past, some significant empirical developments have been made in the 
forms of qualitative and quantitative studies that have explored experiences of cancer patients when they use 
CAM. Such studies have made a fine contribution to knowledge on the use of CAM in different social contexts, 
such as ethnicity, gender, and cultural backgrounds in relation to health practices and beliefs.17 In one such study, 
Shippee et al. established that Black Americans tend to prefer CAM to cisplatin therapy because of high 
perceptions of racial discrimination in medical context.18 
While more social researchers are currently throwing their weight behind CAM, it is not clear how social 
dynamics affect the decision to use cisplatin due to its side-effects like severe nephrotoxicity.19 Typically, social 
phenomena that generate significant controversy in the larger society appeal to sociologists. Early sociological 
research concentrated on users of CAM with explanations for this including the degree of discontent with the 
health outcomes of conventional medicine, cultural norms and practices that have tended to prefer use of 
alternative medicine, and the social approval of the level in which alternative therapists understand ingrained 
cultural practices. This has presented challenges to usage of conventional medicine. In spite of this, there is a 
growing understanding in research of the potential of combining conventional medicine and CAM. It is expected 
that a more sophisticated quantitative research is necessary to demonstrate how nephrotoxicity can be 
counteracted to ensure social acceptance of CAM as an adjunctive to cisplatin therapy. 
Cisplatin (cis-diamminedichloroplatinum II) has been widely used in the treatment of various cancers,20 
such as those of the brain, ovary, bladder, and colon cancer,21and is one of the most effective anticancer agents 
available. The anticancer mechanism of cisplatin involves binding to DNA, the formation of inter- and intra-
strand crosslinks that can activate several signal transduction pathways, and the activation of apoptosis. 22 
However, it is limited by associated toxicities, which include nephrotoxicity, ototoxicity, gastrointestinal 
disorders, and allergic reactions.23 
Cisplatin can cause the accumulation of platinum within the kidney and thus inhibit renal tubular tissue and 
function. The pathophysiology of cisplatin nephrotoxicity is a complicated process and involves vascular, tubular, 
glomerular and interstitial destruction that can lead to chronic renal disease.1 Moreover, it causes dose-dependent 
toxicity and cumulative nephrotoxicity which causes severe symptoms. The mechanism underlying cisplatin 
nephrotoxicity in the kidney involves: decreased renal blood flow,2 tubular necrosis/apoptosis,3) increased lipid 
peroxidation and decreased antioxidant system,4) increased inflammation markers, and increased apoptotic 
activity (caspase-3).24 Nephrotoxicity caused by platinum-based anticancer drugs, such as cisplatin results from 
free radical generation, and oxidative stress and can be relieved by antioxidants.25Oxidation reactions can 
produce free radicals, which start from chain reactions and cause severe disease in humans. Consequently, it 
leads to a decrease in natural cell antioxidant capacity or an increase in reactive oxygen species (ROS) in the 
kidney. Antioxidants are a potential therapeutic method to detoxify ROS in the kidney.5) Antioxidants are 
bioactive molecules that have the ability to decrease or prevent the oxidation of substrate molecules26). In other 
words, the use of antioxidants in combination with cancer drugs can decrease the risk of cisplatin induced 
nephrotoxicity by reducing oxidative stress.27 
Recent studies have focused on the function of antioxidants in cisplatin toxicity because cisplatin-induced 
nephrotoxicity occurs through the induction of oxidative stress, and is inhibited by antioxidant therapies, such as 
vitamin C.28 Given that vitamin C is a powerful antioxidant, it can protect cells from oxidative damage by 
blocking free radicals 29). These antioxidants may detoxify ROS in the kidney without altering the anticancer 
efficacy of cisplatin. Therefore, antioxidants are a promising therapeutic method. Vitamin C largely prevents the 
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functional and structural lesions in the tubules of the kidney. Cisplatin-induced mitochondrial production of 
oxidants was inhibited by vitamin C which is the key to its ability to injure mitochondria30). In a previous study, 
the improvement in renal function following the oral administration, of a combination of different vitamins or of 
vitamins with other agents effectively protected against oxidative organ damages.31 The dosage of vitamin C was 
lower than that in the present research and was not considered as high dose. A previous study has reported that 
high dose vitamin C (1000 mg/kg) can aggravate renal injury as vitamin C enhances oxalate excretion.32 
Ascorbate radicals and hydrogen peroxide are correlated with the oxidative damage observed in renal epithelial 
cells33). However, the administration of high-dose vitamin C alone had no side effects on renal function although 




1) Animal experiments 
Eight-week-old, male ICR mice were purchased from Raonbio (Yongin, Korea) and were housed for 
acclimatization for 7 days prior to the experiment. The mice were randomly divided into five groups each 
containing six mice: control, cisplatin, and cisplatin with 500-, 1000-, and 2000 mg/kg vitamin C. All groups 
except the control group were administered 5-mg/kg cisplatin intraperitoneally for 10 days and mice in 
respective groups were orally administered each 500-, 1000-, and 2000- mg/kg vitamin C diluted in water 2 h 
before cisplatin treatment.The mice were housed at 25ºC ± 2ºCin a humidity of 55% ± 5% under a 12 h 
light/dark cycle. After 10 days, all mice were humanely killed. Blood samples and kidney tissue were collected 
for further analysis. The Institutional Animal Care and Use Committee of Kyung Hee University approved the 
experimental animal facility and protocols. All experimental procedures were performed in compliance with the 
NIH Guide for the Care and Use of Laboratory Animals and National Animal Welfare Law in Korea.  
2) Analysis of blood samples 
Blood samples were collected in test tubes containing EDTA as an anticoagulant. These tubes were placed in an 
icebox and transferred to the laboratory within 1 h of collection. In the laboratory, these samples were 
centrifuged at 3000 rpm for 10 min. The plasma was separated and stored at –4 °C for further analysis. Serum 
creatinine, uric acid and blood urea nitrogen (BUN) were measured using a colorimetric assay kit accordance 
with the manufacturer’s instructions. BUN, uric acid and serum creatinine levels were measured as the indicators 
of kidney function.  
3) Tissue preparation 
Mice in the control group, cisplatin control group, and cisplatin vitamin C (500, 1000, 2000 mg/kg) groups were 
deeply anesthetized using diethyl ether. Subsequently, blood samples werecollected. Thekidney was frozen 
immediately in liquid nitrogen, and stored at –80°C until use.  
4) Real-time quantitative (qRT)-PCR 
In accordance with the manufacturer’s protocol, total RNA was extracted using Trizol reagent from the kidney 
tissues isolated from mice that were orally administered vitamin C.A The qRT-PCR was performed using a 
previously described procedure with minor modifications. Briefly, RNase-Free DNase (QIAGEN, Venlo, 
Netherlands) was added to RNA samplesto eliminate DNA contamination. The verification of RNA purity and 
integrity was performed by measuring the 260/280 nm absorbance ratio using NanoDrop (ND-1000; NanoDrop 
Technologies, DE).cDNA was synthesized using only RNA samples with an absorbance ratio between 1.8 and 
2.1.qRT-PCR was conducted using a light cycler system (STRATAGENE. CA) with cDNA mixed with SYBR 
Green (TAKARA Co., Ltd., Shiga, and TECAN, Männedorf, Switzerland, Japan). Relative gene expression was 
calculated according to the comparative Ct method using β-actin as the internal standard.  
5) Statistical analysis 
Each result is reported as the mean ± standard error of mean.The statistical significance of differences between 
the control and experimental values was calculated by two-way analysis of variance, which was performed using 
GraphPad Prism5.  
 
Results 
1) Body weight graph 
No mortality related to vitamin C administration after treatment with cisplatin was observed in mice for 10 days 
at any dose. There was a decreasing trend in body weight following cisplatin/ vitamin C (500, 1000, and 2000 
mg/kg) treatment at 4-8 days after cisplatin injection. However, there was an increasing trend in body weight in 
the cisplatin/vitamin C (500, 1000 mg/kg) groups after cisplatin injection for 10 days. Thecisplatin control group 
showed a significant change in the animal physiology, as manifested by a decrease in body weight, compared 
with the normal control group. Thecisplatin control group showed a prolonged decrease (Fig. 1). Vitamin C at 
doses (of 500-, and 1000 mg/kg) resulted in significant relief of these manifestations.  
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The effect of cisplatin and vitamin C on renal function in the experimental groups was examined by usingorgan 
weight. After 10 days of vitamin C administration (500, 1000,and 2000 mg/kg) treatment after cisplatin injection, 
there was no significant changes in the weight of the kidneys and the liver (Table 1). In other words, there were 
no significant changes in the kidney, and liver weight between groups. 
3) Biochemical analysis of blood:Effect on renal function 
Statistically significant differences were observed for a number of parameters (AST, ALT, cholesterol, TG, HDL, 
LDL, creatinine, BUN, anduric acid), particularly in the vitamin C (500, 1000, and 2000 mg/kg) and cisplatin 
treated groups. It is thought that these events were related to vitamin C exposure, but they did not occur in a dose 
responsive manner (Fig. 2). The effects of cisplatin and vitamin C on renal function in the experimental groups 
was evaluated by AST, ALT, cholesterol, TG, HDL, and LDL in this study (Fig. 2). Cisplatin administration 
decreased AST, ALT, cholesterol, TG, and LDL and increased HDL compared with the normal control group. 
In particular, cisplatin nephrotoxicity is shown by a clinical increase in the elevation of BUN, serum 
creatinine, proteinuria, and hyperuricemia4). The effect of cisplatin and vitamin C on renal function in the 
experimental groups was evaluated through creatinine, BUN, and uric acid (Fig. 2). Cisplatin administration 
increased creatinine, BUN, and uric acid in the cisplatin control group compared with the normal control group. 
Animals treated with vitamin 500, 1000, and 2000 mg/kg showed differences compared with cisplatin control 
group but no dose-response relationship was observed.  
In the vitamin C treatment groups, biochemical parameters were normalized compared with the cisplatin 
controlgroup.  
4) qRT-PCR : Effect on renal inflammatory cytokines 
The levels of pro-inflammatory cytokines, IL-1β, TNFα, and IL-6 in the kidney homogenate of the experimental 
groups were estimated byqRT-PCR in accordance with the manufacturer’s protocols. The effects of cisplatin and 
vitamin C on the level of renal pro-inflammatory cytokinesin the experimental groups are shown in Fig. 
3.Cisplatin administration resulted in a significant increase in IL-1β, TNFα, and IL-6 compared with the normal 
control group. Vitamin C administration at a doses of 500, 1000, and 2000 mg/kg attenuated the increase in IL-
1β, TNFα, and IL-6 compared with the cisplatin control group, but no dose-response relationship was observed.  
 
Discussion 
The platinum derivative cisplatin has limited therapeutic efficacy owing to its nephrotoxicity which primarily 
affects the S3 segment of the proximal renal tubule35). It is known thatthe release of pro-inflammatory cytokines, 
the recruitment of inflammatory cells and mitochondrial dysfunction leads to the formation of ROS and damage 
to renal tissue36). Oxidative stress and inflammation are two of the most important causes of cisplatin-induced 
nephrotoxicity37). Therefore, the enhancement of antioxidant defenses in renal tissue by antioxidants may be a 
beneficial strategy for protection against cisplatin nephrotoxicity. In this context, a strategy that targets multiple 
mechanisms including the suppression of free radical production and from pro-inflammatory cytokines and the 
amelioration of blood biochemical parameters in the kidney may offer meaningful prevention against 
nephrotoxicity by using high-dose vitamin C therapy because the antioxidant effect of vitamin C can be 
beneficial when co-administered with cisplatin. 
In other studies, cisplatin significantly increased the total ROS, MDA, oxidative stress, and protein carbonyl 
levels in the kidney tissues38). In addition, the antioxidants glutathione (GSH) and vitamin C were significantly 
reduced in cisplatin control group.  
A single dose of cisplatin (5 mg/kg) to the mice resulted in nephrotoxicity in the cisplatin control group. 
BUN, creatinine, and uric acid are the kidney function biomarkers associated with kidney pathologies, and a 
significant increase in BUN, creatinine, anduric acid levels were observed in the cisplatin control group (Fig. 2). 
This was further supported by a decrease in body weight in the cisplatin control group compared with that in the 
normal group (Fig. 1). These results support earlier findings on cisplatin nephrotoxicity. The doses of vitamin C 
(500, 1000, and 2000 mg/kg) reduced levels of uric acid, AST, ALT, cholesterol, triglyceride, LDL, and 
increased HDL levels.  
Non-enzymatic antioxidants, such as vitamin C have immunomodulatory effects. It is an antioxidant, and 
therefore protects important biomolecules from damage by scavenging free radicals or by converting the toxic 
radicals to non-toxic products39). These outcomes indicate the antioxidant activity of vitamin C and the possible 
mechanisms underlyingrenoprotective activity.  
Several reports have suggested that vitamin C exerts anti-inflammatory activity through the inhibition of 
inflammatory cytokines 40 ). Inflammation plays an important role in the pathogenesis of cisplatin-induced 
nephrotoxicity. TNFα, IL-1β, and IL-6 has been reported asimportant pathogenic factors in cisplatin-induced 
nephrotoxicity. As vitamin C can systemically modulate cytokines in a complex manner, the addition of vitamin 
C decreased the generation of the pro-inflammatory cytokines TNFα, IL-1β, and IL-6 (Fig. 3). Vitamin C (500, 
1000, 2000 mg/kg) significantly decreased the level of inflammatory cytokines, implying that itprotects the 
Journal of Health, Medicine and Nursing                                                                                                                                          www.iiste.org 




kidney from inflammatory insulation.41 This is indicative of the anti-inflammatory action.  
Furthermore, vitamin C enhanced or normalized the levels of the antiviral cytokine IFNγ. Moreover, the 
product of iNOS catalysis, nitric oxide (NO), is an important regulator of COX-2 expression, and can also 
influence iNOS expression (Dolores and Santiago, 2004). Cisplatin significantly reduced the renal tissue nitrite 
levels, the extent of NO, in the kidney tissues of the cisplatin group.42 In other words,NO augmentation exerts a 
renoprotective effects against cisplatin nephrotoxicity. In this study, iNOSlevels were increased in the vitamin C 
treatment group.  
 
Conclusion 
As a result of its antioxidant, immunomodulatory, and anti-inflammatory activity, vitamin C can protect the 
kidney from cisplatin-induced kidneys damage. Our findings suggest that high-dose vitamin C can be used the 
prevention of nephrotoxicity in cisplatin-based cancer chemotherapy. The capacity of this research to 
demonstrate that nephrotoxicity can be reduced is indeed beneficial in changing the prevalent social perceptions 
regarding side-effects of conventional therapy such as chemotherapy. By demonstrating how nephrotoxicity can 
be counteracted, the results of this research overturn negative attitudes towards conventional therapy. It is 
expected to promote a high social acceptance of CAM as an adjunctive to cisplatin therapy. Future studies 
involving a selection of patients could help confirm whether high-dose vitamin C prevents nephrotoxicity in 
cisplatin-based cancer chemotherapy. It is possible that the type of adaptability and resilience enabled by vitamin 
C buffers adverse effects of nephrotoxicity. Future research is needed to investigate this relationship, at the 
population level and how it affects societal attitudes towards use of chemotherapy and radiotherapy.  
 
Disclosure statement 
No competing financial interesting exist. 
 
Funding 




1 Gale N. The sociology of traditional, complementary and alternative medicine. Sociology compass. 2014; 8(6): 
805–822. 
2 Barner JC, Bohman TM, Brown CM, Richards KM. Use of complementary and alternative medicine for 
treatment among African-Americans: a multivariate analysis. Res Social Adm Pharm. 2010;6(3):196-208. 
3 Ock, SM, Choi JY, Cha YS, Lee J, Chun MS, Huh CH, Lee SY, Lee SJ. The use of complementary and 
alternative medicine in a general population in South Korea: results from a national survey in 2006. Journal of 
Korean Medical Science.2009. 24(1): 1–6. 
4 Kim MJ, Lee SD, Kim DR, Kong YH, Sohn WS, Ki SS, Kim J, Kim YC, Han C J, Lee JO, Nam HS, Park YH, 
Kim CH, Yi KH, Lee YY, Jeong SH. Use of complementary and alternative medicine among Korean cancer 
patients. The Korean journal of internal medicine. 2004; 19(4): 250–256. 
5  Axelrod R, Pienta K. Cancer as a Social Dysfunction—Why Cancer Research Needs New Thinking." 
Molecular Cancer Research. 2018; 16(9): 1-12. 
6 Kim MJ, Lee SD, Kim DR, Kong YH, Sohn WS, Ki SS, Kim J, Kim YC, Han C J, Lee JO, Nam HS, Park YH, 
Kim CH, Yi KH, Lee YY, Jeong SH. Use of complementary and alternative medicine among Korean cancer 
patients. The Korean journal of internal medicine. 2004; 19(4): 250–256. 
7 Kim J, Kim SM, Jung H, Jung YH, Chang WJ, Choi MK, Kim HS, Sun J, Park K, Myung-Ju A. Efficacy and 
safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the 
head and neck. Korean J Intern Med. 2019;34(5):1107-1115 
8 Choi IS, Choi M, Lee JH, Kim JH, Suh KJ, Lee JY, et al. Treatment patterns and outcomes in patients with 
metastatic gastric cancer receiving third-line chemotherapy: A populationbased outcomes study. PLoS ONE. 
2018; 13(6): 1. 
9 Park HR, Ju E, Jo SK, Jung U, Kim SH, Yee, ST. Enhanced antitumor efficacy of cisplatin in combination with 
HemoHIM in tumor-bearing mice. BMC cancer. 2009; 9: 85. 
10 Park HR, Ju E, Jo SK, Jung U, Kim SH, Yee, ST. Enhanced antitumor efficacy of cisplatin in combination 
with HemoHIM in tumor-bearing mice. BMC cancer. 2009; 9: 85. 
11 Kim J, Kim SM, Jung H, Jung YH, Chang WJ, Choi MK, Kim HS, Sun J, Park K, Myung-Ju A. Efficacy and 
safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the 
head and neck. Korean J Intern Med. 2019;34(5):1107-1115 
12 Kim, S, Kim, B,  Kim, J.  The Use of Complementary and Alternative Medicine among Korean Young Adult 
Members of Fitness Centers. Evidence-Based Complementary and Alternative Medicine. 2019;1: 1-9. 
Journal of Health, Medicine and Nursing                                                                                                                                          www.iiste.org 





13 Gale N. The sociology of traditional, complementary and alternative medicine. Sociology compass. 2014; 
8(6): 805–822. 
14 Kim, S, Kim, B,  Kim, J.  The Use of Complementary and Alternative Medicine among Korean Young Adult 
Members of Fitness Centers. Evidence-Based Complementary and Alternative Medicine. 2019;1: 1-9. 
15 Hae-Ran P, Eun-Jin J, Sung-Kee J, Jung U, Sung-Ho K, Sung-Tae Y. Enhanced antitumor efficacy of cisplatin 
in combination with HemoHIM in tumor-bearing mice. BMC Cancer. 2009; 9(85):1 
16 Ock, SM, Choi JY, Cha YS, Lee J, Chun MS, Huh CH, Lee SY, Lee SJ. The use of complementary and 
alternative medicine in a general population in South Korea: results from a national survey in 2006. Journal of 
Korean Medical Science.2009. 24(1): 1–6. 
17 Shippee, T. P., Schafer, M. H., & Ferraro, K. F. (2012). Beyond the barriers: racial discrimination and use of 
complementary and alternative medicine among Black Americans. Social science & medicine. 1982; 74(8): 
1155–1162. 
18 Shippee, T. P., Schafer, M. H., & Ferraro, K. F. (2012). Beyond the barriers: racial discrimination and use of 
complementary and alternative medicine among Black Americans. Social science & medicine. 1982; 74(8): 
1155–1162. 
19 Kim, S, Kim, B,  Kim, J.  The Use of Complementary and Alternative Medicine among Korean Young Adult 
Members of Fitness Centers. Evidence-Based Complementary and Alternative Medicine. 2019;1: 1-9. 
20Miller RP, Tadagavadi RK, Ramesh G, et al. Mechanisms of Cisplatin nephrotoxicity. Toxins.2010;2(11): 
2490-2518. 
21Rosenberg B. Platinum coordination complexes in cancer chemotherapy. Naturwissenschaften. 1973;60(9): 
399-406. 
22Stefan Aebi, Buran Kurdi-Haidar, Robert Gordon, et al. Loss of DNA Mismatch Repair in Acquired Resistance 
to Cisplatin.Cancer Research. 1996; 56:3087-3090. 
23Madias NE, Harrington JT. Platinum nephrotoxicity. The American Journal of Medicine. 1978;65(2) :307-314. 
24Hajia S, Rafieian-Kopaei M, Nasri H. Renoprotective effects of antioxidants against cisplatin nephrotoxicity. 
Journal of Nephropharmacology. 2014;3(2): 39-42. 
25 Santos NA, Bezerra CS, Martins NM, et al. Hydroxyl radical scavenger ameliorates cisplatin-induced 
nephrotoxicity by preventing oxidative stress, redox state unbalance, impairment of energetic metabolism and 
apoptosis in rat kidney mitochondria. Cancer chemotherapy and Pharmacology. 2008; 61(1): 145-155. 
26Bagheri N, Rahimian G, Salimzadeh L, et al. Association of the virulence factors of Helicobacter pylori and 
gastric mucosal interleukin-17/23 mRNA expression in dyspeptic patients. Experimental and Clinical Sciences. 
2013; 12:5-14. 
27Nasri H. Cisplatin and renal injury; current concepts. Journal of Renal Injury Prevention.2013; 2(3): 89-90. 
28 Nasri H. Cisplatin and renal injury; current concepts. Journal of Renal Injury Prevention.2013; 2(3): 89-90. 
29Kim TJ, Byun JS, Kwon HS, et al. Cellular toxicity driven by high-dose vitamin C on normal and cancer stem 
cells. Biochemical and Biophysical Research communications.2018; 497(1): 347-353. 
30Mukhopadhyay P, Horváth B, Zsengellér Z, et al. Mitochondrial-targeted antioxidants represent a promising 
approach for prevention of cisplatin-induced nephropathy.Free Radical Biology and Medicine.2012; 52(2):497-
506. 
31Antunes LM, Darin JD, Bianchi MD. Protective effects of vitamin c against cisplatin-induced nephrotoxicity 
and lipid peroxidation in adult rats: a dose-dependent study. Pharmacological Research. Pharmacological 
Research. 2000;41(4): 405-411. 
32Peña de la Vega L, Lieske JC, Milliner D, et al. Urinary oxalate excretion increases in home parenteral 
nutrition patients on a higher intravenous ascorbic acid dose. Journal of Parenteral and Enteral Nutrition. 2004; 
28(6): 435-438. 
33Thamilselvan S, Khan SR, Menon M. Oxalate and calcium oxalate mediated free radical toxicity in renal 
epithelial cells: effect of antioxidants. 2003; Urological Research.31(1): 3-9. 
34Gurm H, Sheta MA, Nivera N, et al. Vitamin C-induced oxalate nephropathy: a case report. Journal of 
Community Hospital Internal Medicine Perspectives. 2012; 16;2(2). 
35Sahu BD, Rentam KK, Putcha UK, Kuncha M, Vegi GM, Sistla R (2011) Carnosic acid attenuates renal injury 
in an experimental model of rat cisplatin-induced nephrotoxicity. Food Chemical Toxicology. 49(12):3090-3097. 
36Oh GS, Kim HJ, Shen A, et al. New Therapeutic Concept of NAD Redox Balance for Cisplatin Nephrotoxicity. 
BioMed research international. 2016:4048390 
37Kilic U, Kilic E, Tuzcu Z, et al. Melatonin suppresses cisplatin-induced nephrotoxicity via activation of Nrf-
2/HO-1 pathway. Nutrition & Metabolism. 2013; 10(1): 7. 
38  Sahu BD, Kuncha M, Sindhura GJ, et al. Hesperidin attenuates cisplatin-induced acute renal injury by 
decreasing oxidative stress, inflammation and DNA damage. Phytomedicine. 2013; 20(5):453-460. 
39Carr AC, Maggini S. Vitamin C and Immune Function. Nutrients. 2017; 9(11). 
Journal of Health, Medicine and Nursing                                                                                                                                          www.iiste.org 





40Molina N, Morandi AC, Bolin AP, et al. Comparative effect of fucoxanthin and vitamin C on oxidative and 
functional parameters of human lymphocytes. International Immunopharmacology. 2014; 22(1):41-50. 
41Chen Y, Luo G, Yuan J, et al. Vitamin C mitigates oxidative stress and tumor necrosis factor-alpha in severe 
community-acquired pneumonia and LPS-induced macrophages. Mediators Inflammation. 2014:426740. 
42Dolores pérez-Sala, Santiago Lamas. Regulation of cyclooxygenase-2 expression by nitric oxide in cells. 
Antioxidants & Redox Signaling. 2004; 3(2): 231-248. 
